ArticleCancers2022

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease.

Hisato Kawakami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.